Article thumbnail

Directed adenovirus evolution using engineered mutator viral polymerases

By Taco G. Uil, Jort Vellinga, Jeroen de Vrij, Sanne K. van den Hengel, Martijn J. W. E. Rabelink, Steve J. Cramer, Julia J. M. Eekels, Yavuz Ariyurek, Michiel van Galen and Rob C. Hoeben


Adenoviruses (Ads) are the most frequently used viruses for oncolytic and gene therapy purposes. Most Ad-based vectors have been generated through rational design. Although this led to significant vector improvements, it is often hampered by an insufficient understanding of Ad’s intricate functions and interactions. Here, to evade this issue, we adopted a novel, mutator Ad polymerase-based, ‘accelerated-evolution’ approach that can serve as general method to generate or optimize adenoviral vectors. First, we site specifically substituted Ad polymerase residues located in either the nucleotide binding pocket or the exonuclease domain. This yielded several polymerase mutants that, while fully supportive of viral replication, increased Ad’s intrinsic mutation rate. Mutator activities of these mutants were revealed by performing deep sequencing on pools of replicated viruses. The strongest identified mutators carried replacements of residues implicated in ssDNA binding at the exonuclease active site. Next, we exploited these mutators to generate the genetic diversity required for directed Ad evolution. Using this new forward genetics approach, we isolated viral mutants with improved cytolytic activity. These mutants revealed a common mutation in a splice acceptor site preceding the gene for the adenovirus death protein (ADP). Accordingly, the isolated viruses showed high and untimely expression of ADP, correlating with a severe deregulation of E3 transcript splicing

Topics: Methods Online
Publisher: Oxford University Press
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1994). 30–>50 exonuclease active site of phi 29 DNA polymerase. Evidence favoring a metal ion-assisted reaction mechanism.
  2. (1989). A conserved 30—-50 exonuclease active site in prokaryotic and eukaryotic DNA polymerases.
  3. (2000). a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.
  4. (2009). A lentiviral vector-based adenovirus fiber-pseudotyping approach for expedited functional assessment of candidate retargeted fibers.
  5. (2007). A novel method for generating and screening peptides and libraries displayed on adenovirus fiber.
  6. (2001). A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy.
  7. (2008). Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant.
  8. (2001). Adaptation of chimeric retroviruses in vitro and in vivo: isolation of avian retroviral vectors with extended host range.
  9. (1998). Adaptation of Sindbis virus to BHK cells selects for use of heparan sulfate as an attachment receptor.
  10. (2007). Adaptive evolution of a tagged chimeric gammaretrovirus: identification of novel cis-acting elements that modulate splicing.
  11. (2003). Adenovirus DNA replication.
  12. (2005). ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis.
  13. (1990). An attempt to unify the structure of polymerases.
  14. (2008). Bioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potency.
  15. (2003). Changes in rhinovirus protein 2C allow efficient replication in mouse cells.
  16. (2008). Changing the protease specificity for activation of a flavivirus, tick-borne encephalitis virus.
  17. (1996). Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors.
  18. (2007). Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance.
  19. (1979). Complex splicing patterns of RNAs from the early regions of adenovirus-2.
  20. (2002). Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency.
  21. (2009). Deep sequencing to reveal new variants in pooled DNA samples.
  22. (2009). Designing adenoviral vectors for tumor-specific targeting. Methods Mol.
  23. (2003). Developing novel oncolytic adenoviruses through bioselection.
  24. (2007). Direct selection of targeted adenovirus vectors by random peptide display on the fiber knob.
  25. (2008). Directed evolution generates a novel oncolytic virus for the treatment of colon cancer.
  26. (2006). Directed evolution of adeno-associated virus yields enhanced gene delivery vectors.
  27. (2004). DNA replication fidelity.
  28. (1997). Effects of mutations in the Exo III motif of the herpes simplex virus DNA polymerase gene on enzyme activities, viral replication, and replication fidelity.
  29. (2004). Enhanced cellular receptor usage by a bioselected variant of coxsackievirus a21.
  30. (2006). Genetic identification of adenovirus type 5 genes that influence viral spread.
  31. (2001). Getting a grip on how DNA polymerases function.
  32. (1988). Human DNA polymerase alpha gene expression is cell proliferation dependent and its primary structure is similar to both prokaryotic and eukaryotic replicative DNA polymerases.
  33. (2004). Insights into strand displacement and processivity from the crystal structure of the protein-primed DNA polymerase of bacteriophage phi29.
  34. (2001). Interacting fidelity defects in the replicative DNA polymerase of bacteriophage RB69.
  35. (2002). Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein.
  36. (2001). Lentivirus vectors encoding both central polypurine tract and posttranscriptional regulatory element provide enhanced transduction and transgene expression.
  37. (2004). Low-fidelity Pyrococcus furiosus DNA polymerase mutants useful in error-prone PCR.
  38. (1984). Mapping a new gene that encodes an 11,600-molecular-weight protein in the E3 transcription unit of adenovirus 2.
  39. (1985). Mapping the 50 ends, 30 ends, and splice sites of mRNAs from the early E3 transcription unit of adenovirus 5.
  40. (2000). Molecular breeding of viruses.
  41. (2008). Molecular engineering of viral gene delivery vehicles.
  42. (1998). Molecular evolution by staggered extension process (StEP) in vitro recombination.
  43. (1999). Mutation rates among RNA viruses.
  44. (1998). Mutational analysis of phi29 DNA polymerase residues acting as ssDNA ligands for 30-50 exonucleolysis.
  45. (2009). Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution.
  46. (1996). Primer-terminus stabilization at the 30-50 exonuclease active site of phi29 DNA polymerase. Involvement of two amino acid residues highly conserved in proofreading DNA polymerases.
  47. (1997). Processive proofreading by the adenovirus DNA polymerase. Association with the priming protein reduces exonucleolytic degradation.
  48. (2009). Quantification of rare allelic variants from pooled genomic DNA.
  49. (1999). Quantitation of adenovirus DNA and virus particles with the PicoGreen fluorescent Dye.
  50. (2006). Rapid adaptation of a recombinant vesicular stomatitis virus to a targeted cell line.
  51. (1994). Rapid evolution of a protein in vitro by DNA shuffling.
  52. (1998). Rates of spontaneous mutation.
  53. (2001). Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy.
  54. (2005). Recent progress in the battle between oncolytic viruses and tumours.
  55. (2006). Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species.
  56. (2002). RNA viruses as virotherapy agents.
  57. (2006). Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity.
  58. (2006). Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing.
  59. (2008). Sequencing of natural strains of Arabidopsis thaliana with short reads.
  60. (2009). Simultaneous alignment of short reads against multiple genomes.
  61. (1992). Site-directed mutagenesis at the Exo III motif of phi 29 DNA polymerase; overlapping structural domains for the 30-50 exonuclease and strand-displacement activities.
  62. (2004). Solution structure of a nitrous acid induced DNA interstrand cross-link.
  63. (1992). The 11,600-MW protein encoded by region E3 of adenovirus is expressed early but is greatly amplified at late stages of infection.
  64. (1996). The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells.
  65. (2008). The optimal burst of mutation to create a phenotype.
  66. (2005). The viral polymerase mediates adaptation of an avian influenza virus to a mammalian host.
  67. (1990). Transformation and immortalization of diploid xeroderma pigmentosum fibroblasts.
  68. (2000). Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein.
  69. (1964). Two separable effects of hydroxylamine on transforming DNA.
  70. (2008). Velvet: algorithms for de novo short read assembly using de Bruijn graphs.
  71. (2001). Viral evolution toward change in receptor usage: adaptation of a major group human rhinovirus to grow in ICAM-1-negative cells.